ALTIMMUNE INC (ALT:NASDAQ)
$2.62 -0.02 (-0.7576%)
Analysed ALTIMMUNE INC (ALT:NASDAQ) News Sources
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
27-05-2026
yahoo.com
Altimmune to Participate in Upcoming Investor Conferences
27-05-2026
yahoo.com
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
28-05-2026
yahoo.com
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
05-06-2026
marketbeat.com
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
08-06-2026
yahoo.com
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
08-06-2026
yahoo.com
ALT and the Rise of Dual Agonists Targeting Liver Disease
08-06-2026
yahoo.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
08-06-2026
yahoo.com
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
10-06-2026
marketbeat.com
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?
12-06-2026
yahoo.com
What is the current price of ALTIMMUNE INC (ALT:NASDAQ)?
The current price of ALTIMMUNE INC (ALT:NASDAQ) is $2.62.
ALTIMMUNE INC (ALT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALTIMMUNE INC (ALT:NASDAQ) since the previous trading day is $-0.02.
ALTIMMUNE INC (ALT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALTIMMUNE INC (ALT:NASDAQ) since the previous trading day is -0.7576%.
What is the most recent average sentiment score for ALTIMMUNE INC (ALT:NASDAQ)?
The most recent average sentiment score for ALTIMMUNE INC (ALT:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for ALTIMMUNE INC (ALT:NASDAQ)?
The most recent sentiment for ALTIMMUNE INC (ALT:NASDAQ) is .
SEC-8K** Filing Available For ALTIMMUNE INC (ALT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.